Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
- PMID: 12528778
- DOI: 10.1016/s0959-8049(02)80608-6
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
Abstract
In a phase I study conducted by the EORTC Soft Tissue and Bone Sarcoma Group, 40 patients with advanced soft tissue sarcomas, most of whom had gastrointestinal stromal tumors (GISTs), received imatinib at doses of 400 mg q.d., 300 mg b.i.d., 400 mg b.i.d., or 500 mg b.i.d. Dose-limiting toxicities, including severe nausea, vomiting, edema and rash, were seen at the highest dose level; the maximum tolerated dose was therefore 400 mg b.i.d. Imatinib was active in the group of 35 patients with GISTs, producing partial responses in 19 (54%) patients and stable disease in 13 patients (37%). Responding patients have now been followed for a minimum of 10 months. The most common side effects seen in patients continuing on therapy have been periorbital edema (40%), peripheral edema (37.5%), fatigue (30%), skin rash (30%) and nausea/vomiting (25%). Severe late myelosuppression has also been seen occasionally. Eighteen (51%) GIST patients continue to have partial responses and 11 (31%) continue with stable disease. Thus, 82% of patients with GISTs are still obtaining clinically important benefits with continued imatinib therapy. Some patients showed accelerated progressive disease shortly after starting imatinib. On the other hand, following drug withdrawal, 2 patients had reductions in tumor burden and remain alive without drug therapy. In summary, imatinib is generally well tolerated and has significant activity during long-term treatment of patients with advanced GISTs.
Similar articles
-
Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.Eur J Cancer. 2002 Sep;38 Suppl 5:S66-9. doi: 10.1016/s0959-8049(02)80605-0. Eur J Cancer. 2002. PMID: 12528775 Review.
-
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.Lancet. 2001 Oct 27;358(9291):1421-3. doi: 10.1016/s0140-6736(01)06535-7. Lancet. 2001. PMID: 11705489 Clinical Trial.
-
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.Eur J Cancer. 2003 Sep;39(14):2006-11. Eur J Cancer. 2003. PMID: 12957454 Clinical Trial.
-
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.Drugs. 2003;63(5):513-22; discussion 523-4. doi: 10.2165/00003495-200363050-00005. Drugs. 2003. PMID: 12600228 Review.
-
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.Clin Cancer Res. 2002 Oct;8(10):3034-8. Clin Cancer Res. 2002. PMID: 12374669 Clinical Trial.
Cited by
-
The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment.Cancers (Basel). 2023 Nov 5;15(21):5294. doi: 10.3390/cancers15215294. Cancers (Basel). 2023. PMID: 37958467 Free PMC article. Review.
-
A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor.Front Pharmacol. 2022 Nov 21;13:978885. doi: 10.3389/fphar.2022.978885. eCollection 2022. Front Pharmacol. 2022. PMID: 36479203 Free PMC article.
-
Characteristics of 18F-FDG and 18F-FDOPA PET in an 8-year-old neutered male Yorkshire Terrier dog with glioma: long-term chemotherapy using hydroxyurea plus imatinib with prednisolone and immunoreactivity for PDGFR-β and LAT1.Vet Q. 2021 Dec;41(1):163-171. doi: 10.1080/01652176.2021.1906466. Vet Q. 2021. PMID: 33745419 Free PMC article.
-
The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients.Biomedicines. 2020 Dec 22;9(1):2. doi: 10.3390/biomedicines9010002. Biomedicines. 2020. PMID: 33375183 Free PMC article. Review.
-
Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors.Surg Today. 2019 Jun;49(6):460-466. doi: 10.1007/s00595-018-1737-5. Epub 2018 Nov 15. Surg Today. 2019. PMID: 30443673 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical